Patient Characteristics (n = 105)
| Characteristic | Data |
|---|---|
| Age (y) | 71 (46–82) |
| Initial tumor stage | |
| pT2a | 1 (1%) |
| pT2c | 16 (15%) |
| pT3a | 29 (28%) |
| pT3b | 55 (52%) |
| pT4 | 3 (3%) |
| Unknown | 1 (1%) |
| Initial nodal stage | |
| pN0 in patients with PSA… | |
| Persistence | 35 (47%) |
| Recurrence | 22 (73%) |
| pN1 in patients with PSA… | |
| Persistence | 40 (53%) |
| Recurrence | 5 (17%) |
| pNx/cN0 in patients with PSA… | |
| Persistence | 0 (0%) |
| Recurrence | 1 (3%) |
| Unknown | 0 (0%)/2 (7%) |
| Number of removed LNs | 12 (2–42) |
| Positive surgical margins | 56 (53%) |
| International Society of Urological Pathology score | |
| 1 | 2 (2%) |
| 2 | 12 (11%) |
| 3 | 23 (22%) |
| 4 | 19 (18%) |
| 5 | 48 (46%) |
| Unknown | 1 (1%) |
| PSA at diagnosis (ng/mL) | 15.1 (1.6–332) |
| Postoperative PSA (ng/mL) | 0.6 (0.0–58.0) |
| Patients with PSA… | |
| Persistence | 75 (71%) |
| Recurrence | 30 (29%) |
| PSA at PSMA PET/CT (ng/mL) in patients with PSA… | |
| Persistence | 1.65 (0.10–40.13) |
| Recurrence | 0.75 (0.22–55.65) |
| Patients with… | |
| 68Ga-PSMA PET/CT | 68 (65%) |
| 18F-PSMA PET/CT | 37 (35%) |
| Activity (MBq) | 241 (87–367) |
| Time from injection to PET scan (min) | 66 (45–125) |
| Patients with additional… | |
| Bone metastases | 13 (12%) |
| Local recurrences | 33 (31%) |
Qualitative data are number and percentage; continuous data are median and range.